Trust Company of Vermont’s BioMarin Pharmaceuticals BMRN Stock Holding History

Trust Company of Vermont’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-100	Closed	-$8.67K	–	817
2023 Q2	$8.67K	Hold	100	–	–	﹤0.01%	691
2023 Q1	$9.72K	Hold	100	–	–	﹤0.01%	713
2022 Q4	$10.3K	Hold	100	–	–	﹤0.01%	683
2022 Q3	$8K	Buy	100 +71	+245%	+$6.32K	﹤0.01%	750
2022 Q2	$2K	Buy	+29	New	+$2.31K	﹤0.01%	854
2021 Q1	–	Sell	-100	Closed	-$9K	–	758
2020 Q4	$9K	Hold	100	–	–	﹤0.01%	635
2020 Q3	$8K	Hold	100	–	–	﹤0.01%	625
2020 Q2	$12K	Hold	100	–	–	﹤0.01%	594
2020 Q1	$8K	Hold	100	–	–	﹤0.01%	682
2019 Q4	$8K	Sell	100 -150	-60%	-$11.3K	﹤0.01%	732
2019 Q3	$17K	Sell	250 -250	-50%	-$19.3K	﹤0.01%	649
2019 Q2	$43K	Hold	500	–	–	﹤0.01%	501
2019 Q1	$44K	Buy	+500	New	+$46.3K	﹤0.01%	489

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Trust Company of Vermont's BMRN Position: Q3 2023 in Review

Trust Company of Vermont sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 100 shares — an estimated $8.67K sold.

Trust Company of Vermont first reported a position in BMRN in Q1 2019 and held it in 13 quarters. The position peaked at $44K in Q1 2019. 520 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

Trust Company of Vermont reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Trust Company of Vermont sold 100 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $8.67K.
Trust Company of Vermont first reported a position in BioMarin Pharmaceuticals in Q1 2019 and held it in 13 quarters.
Trust Company of Vermont's BioMarin Pharmaceuticals position peaked at $44K in Q1 2019.
520 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on Trust Company of Vermont's 13F filing for Q3 2023, filed 27 Nov 2023.